Loading...
Galapagos receives €4 million in milestones from Servier
10-Feb-2011
- Belgium
Advertisement
Galapagos NV announced that it reached milestones in its osteoarthritis alliance with Servier, resulting in payments in 2010 revenues totaling €4 million from Servier.
In July 2010, Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis. Galapagos is responsible for the discovery and development of new candidate drugs and Servier has an exclusive option to license these after the completion of Phase I clinical trials by Galapagos. To date, Galapagos has received a total of €11 million in payments from Servier under the alliance.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Ingenuity Technology Licensed by Schering-Plough Research Institute (SPRI) - NEW Ingenuity Pathways Analysis 3.0 Deployed to SPRI Researchers
New target to treat severe autoimmune disease
Nitric oxide may slow progression of COVID-19 - A recent review suggests that nitric oxide has promise as a therapeutic to control the replication and rapid spread of SARS-CoV-2
Genomatix appoints Distributor for the growing Chinese Market
Financial decisions influenced by intensity of light
SOLVO Biotechnology among the region's fastest growing
Detailed chemical structure of P22 virus resolved
Back-to-back: Current Studies on the Longevity of Naked Mole-Rats
Dr. Franz Köhler Chemie GmbH - Bensheim, Germany
